Short interest for Hologic gives investors a sense of the degree to which investors are betting on the decline of Hologic's stock. Short interest data is updated every two weeks.

Hologic Stock (NASDAQ:HOLX), Short Interest Report

Hologic

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Jill Biden

Biotech

Government

News

Health Care

Financing

General

DARE

FEMY

HOLX

Jill Biden announces $100 million in federal funding for women&#39;s health research, addressing underfunding and lack of awareness. ARPA-H Sprint for Women&#39;s Health aims to promote innovative solutions.

First Lady Jill Biden Unveils $100M In Federal Funding To Support R&amp;D - Watch Out for These Women Health Stocks

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

AMZN

DECK

LANC

MCHP

NYCB

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Amazon To Rally Over 41%? Here Are 10 Top Analyst Forecasts For Friday

Hologic.3Dimensions_leaf_4291_EU

Earnings

Earnings Beats

Movers & Shakers

After-Hours Center

Hologic delivered strong revenue and profitability to start fiscal 2024, exceeding the high-end of our guidance for both the top-line and the bottom-line, says CEO.

Hologic Reports Better-Than-Expected Q1 Results

Hologic Inc

Hologic To Acquire Endomagnetics For Approximately $310M; Endomagnetics Generated ~$35M In Revenue In 2023, Acquisition Expected To Be slightly Dilutive To Adj. EPS In FY24, Breakeven In 2025 And Accretive Thereafter

Needham analyst Mike Matson reiterates Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Buy and maintains $90 price target.

Reiteration

Needham Reiterates Buy on Hologic, Maintains $90 Price Target

Evercore ISI Group analyst Vijay Kumar maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a In-Line and raises the price target from $76 to $78.

Evercore ISI Group Maintains In-Line on Hologic, Raises Price Target to $78

In the preceding three months, 4 analysts have released ratings for Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $88.0, a high estimate of $95.00, and a low estimate of $79.00. This upward trend is apparent, with the current average reflecting a 7.98% increase from the previous average price target of $81.50.
<img src="https://www.benzinga.com/files/images/story/2024/1712156436_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Hologic among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Elizabeth Garcia</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$83.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hologic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Hologic compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Hologic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Hologic's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HOLX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hologic analyst ratings.</a>
<h2>Discovering Hologic: A Closer Look</h2>
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
<h3>A Deep Dive into Hologic's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Hologic's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -5.69%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Hologic's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 24.33% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Hologic's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.1% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Hologic's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.8%, the company showcases efficient use of assets and strong financial health.
Debt Management: Hologic's debt-to-equity ratio is below the industry average at 0.55, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Landscape: 4 Takes On Hologic

CORRECTION: Citigroup analyst Patrick Donnelly upgrades Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) from Neutral to Buy and raises the price target from $80 to $95.-Rating change updated
&nbsp;

Upgrades

CORRECTION: Citigroup Upgrades Hologic to Buy, Raises Price Target to $95 - Rating change updated

Citigroup analyst Patrick Donnelly maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Neutral and raises the price target from $80 to $95.

Citigroup Maintains Neutral on Hologic, Raises Price Target to $95

Results From a Large-Scale Prospective Study Investigating Long-Term Anti-Estrogen Therapy Recommendations Published in JNCCN — Journal of the National Comprehensive Cancer Network

Hologic Published Results Suggest Proportion Of Early-Stage HR+ Breast Cancer Survivors May Be Over- Or Undertreated Without Breast Cancer Index Genomic Testing

First Lady&nbsp;Jill Biden&nbsp;unveiled a significant milestone in the White House Initiative on Women&#8217;s Health Research by announcing $100 million in federal funding for research and development for women&#8217;s health.&nbsp;
This move represents a crucial step in addressing the historical underfunding and lack of research into women&#8217;s health issues, a concern highlighted by Biden.
The funding stems from the Advanced Research Projects Agency for Health (ARPA-H), a component of the federal Department of Health and Human Services.&nbsp;
The initiative marks a pivotal moment in advancing solutions to women&#8217;s health problems, the Washington Post&nbsp;<a target="_blank" href="https://www.washingtonpost.com/politics/2024/02/21/jill-biden-research-womens-health-arpah-shriver/889c4020-d0a0-11ee-ac8b-765284b5203e_story.html" rel="noreferrer noopener">noted</a>, aiming to reshape the research landscape and secure increased funding.
President Joe Biden&nbsp;established the Advanced Research Projects Agency for Health in 2022 as part of his &#8220;unity agenda,&#8221; focusing on tackling health challenges.&nbsp;
The newly announced ARPA-H Sprint for Women&#8217;s Health will kick off in the coming weeks, encouraging innovative ideas to propel groundbreaking research and development in women&#8217;s health.
During an appearance in Cambridge, Massachusetts, the First Lady emphasized the lack of awareness among women regarding their health due to historical underfunding in research.&nbsp;
Have a look at the stocks:
<a target="_blank" href="https://www.benzinga.com/quote/HOLX" rel="noreferrer noopener">Hologic Inc</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) markets women&#8217;s diagnostics, including skeletal health and scanner systems and diagnostic products related to Sexually Transmitted Infections.
<a target="_blank" href="https://www.benzinga.com/quote/DARE" rel="noreferrer noopener">Daré Bioscience Inc</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) markets Xaciato (Clindamycin Phosphate) Vaginal Gel 2% indicated for bacterial vaginosis in females 12 years of age and older. The company also has several products under development for contraception, sexual &amp; vaginal health, fertility, and menopause.
<a target="_blank" href="https://www.benzinga.com/quote/awh" rel="noreferrer noopener">Aspira Women&#8217;s Health Inc</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) is focused on ovarian cancer diagnosis. The company developed OvaSuite, a blood test for ovarian cancer, to use with ultrasound checkups (OvaWATCH).
<a target="_blank" href="https://www.benzinga.com/quote/OGN" rel="noreferrer noopener">Organon Inc.&#8217;s</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>) portfolio and pipeline are focused on bacterial vaginosis, breast cancer, contraception, endometriosis, fertility, hysterectomy, menopause, osteoporosis, polycystic ovarian syndrome, and postpartum hemorrhage.
<a target="_blank" href="https://www.benzinga.com/quote/FEMY" rel="noreferrer noopener">Femasys Inc&#8217;s&nbsp;</a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) FemBloc permanent birth control in late-stage clinical development as the first and only non-surgical, in-office, permanent birth control method. Femasys&#8217; FDA-approved FemaSeed Intratubal Insemination is an infertility treatment designed to deliver sperm directly where conception occurs.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Jill Biden Photo By Gage Skidmore On Flickr

First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks

UBS analyst Elizabeth Garcia maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Neutral and raises the price target from $78 to $79.

UBS Maintains Neutral on Hologic, Raises Price Target to $79

Raymond James analyst Andrew Cooper maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Outperform and raises the price target from $85 to $88.

Raymond James Maintains Outperform on Hologic, Raises Price Target to $88

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>JP Morgan cut the price target for WEC Energy Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wec#NYSE">WEC</a>) from $90 to $84. JP Morgan analyst Jeremy Tonet downgraded the stock from Neutral to Underweight. WEC Energy shares gained 1.3% to close at $81.78 on Thursday. <a href="https://www.benzinga.com/quote/WEC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup raised Macy&#39;s, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/m#NYSE">M</a>) price target from $14 to $18. Citigroup analyst Paul Lejuez upgraded the stock from Sell to Neutral. Macy&#39;s shares rose 0.8% to close at $18.44 on Thursday. <a href="https://www.benzinga.com/quote/M/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham boosted the price target for Hologic, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/holx#NASDAQ">HOLX</a>) from $83 to $90. Needham analyst Mike Matson maintained a Buy rating. Hologic shares fell 0.1% to close at $74.41 on Thursday. <a href="https://www.benzinga.com/quote/HOLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan increased Amazon.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>) price target from $190 to $225. JP Morgan analyst Doug Anmuth maintained an Overweight rating. Amazon shares gained 2.6% to close at $159.28 on Thursday. <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James boosted the price target for Roper Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rop#NYSE">ROP</a>) from $572 to $620. Raymond James analyst Brian Gesuale maintained a Strong Buy rating. Roper Technologies shares rose 1.6% to close at $545.81 on Thursday. <a href="https://www.benzinga.com/quote/ROP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group increased the price target for Deckers Outdoor Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/deck#NYSE">DECK</a>) from $850 to $930. Telsey Advisory Group analyst Dana Telsey maintained an Outperform rating. Deckers Outdoor shares gained 2.5% to close at $772.85 on Thursday. <a href="https://www.benzinga.com/quote/DECK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital cut Gold Fields Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gfi#NYSE">GFI</a>) price target from $14 to $12. BMO Capital analyst Andrew Kaip downgraded the stock from Market Perform to Underperform. Gold Fields shares rose 6.8% to close at $15.81 on Thursday. <a href="https://www.benzinga.com/quote/GFI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank slashed New York Community Bancorp, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nycb#NYSE">NYCB</a>) price target from $15 to $7. Deutsche Bank analyst Bernard von-Gizycki downgraded the stock from Buy to Hold. New York Community Bancorp shares dipped 11.1% to close at $5.75 on Thursday. <a href="https://www.benzinga.com/quote/NYCB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham raised Microchip Technology Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mchp#NASDAQ">MCHP</a>) price target from $85&nbsp;to&nbsp;$90. Needham analyst Quinn Bolton maintained a Buy rating. Microchip Technology shares rose 0.6% to close at $85.65 on Thursday. <a href="https://www.benzinga.com/quote/MCHP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. boosted Lancaster Colony Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lanc#NASDAQ">LANC</a>) price target from $205&nbsp;to&nbsp;$218. Stephens &amp; Co. analyst Jim Salera downgraded the stock from Overweight to Equal-Weight. Lancaster Colony shares jumped 11% to close at $204.04 on Thursday. <a href="https://www.benzinga.com/quote/WEC/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/02/36904348/amazon-apple-and-3-stocks-to-watch-heading-into-friday"> Amazon, Apple And 3 Stocks To Watch Heading Into Friday </a>

4 analysts have shared their evaluations of Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $80.5, along with a high estimate of $90.00 and a low estimate of $72.00. A 3.59% drop is evident in the current average compared to the previous average price target of $83.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1706875224_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Hologic among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Elizabeth Garcia</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$82.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$72.00</td>
<td>$74.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Hologic. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Hologic compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Hologic's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Hologic's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HOLX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hologic analyst ratings.</a>
<h2>All You Need to Know About Hologic</h2>
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
<h3>Unraveling the Financial Story of Hologic</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Hologic's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2023, the company experienced a revenue decline of approximately -0.83%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Hologic's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 9.58%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Hologic's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.78%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.98%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Hologic's debt-to-equity ratio is below the industry average at 0.58, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Hologic

Needham analyst Mike Matson maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Buy and raises the price target from $83 to $90.

Needham Maintains Buy on Hologic, Raises Price Target to $90

Hologic Says New Genius Digital Diagnostics System With The Genius Cervical AI Algorithm Received Clearance From FDA

Guidance

Hologic Expects Q2 Revenue Of $990M-$1.01B (Est $998.09M), Adj EPS Of $0.95-$1.00 (Est $0.98)

Hologic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) reported better-than-expected first-quarter financial results after the bell Thursday. Here's a <a href="https://www.benzinga.com/pressreleases/24/02/b36898215/hologic-announces-financial-results-for-first-quarter-of-fiscal-2024">look at the highlights.&nbsp;</a>
The Details: Hologic reported quarterly adjusted earnings of 98 cents per share, beating the analyst consensus estimate of 95 cents by 3.16% and representing an 8.41% decrease over earnings of $1.07 per share from the same period last year. 
Quarterly sales clocked in at $1.01 billion, beating the analyst consensus estimate of $986.12 million by 2.73% and representing a 5.68% decrease over sales of $1.07 billion year-over-year.
Hologic saw second-quarter revenue of between $990 million and $1.01 billion and earnings of between 95 cents and $1.00 per share.
"We delivered strong revenue and profitability to start fiscal 2024, exceeding the high-end of our guidance for both the top-line and the bottom-line. Adjusting for the four fewer selling days in the quarter, we estimate our organic growth rate ex. COVID-19 was in the high single digits, highlighting the bigger, faster, stronger Hologic we are today," said Stephen P. MacMillan, CEO of Hologic. 
HOLX Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Hologic shares are trading down 0.15% after-hours at $74.30 at the time of publication Thursday.
Related News:<a href="https://www.benzinga.com/news/24/01/36827785/whats-going-on-with-rivian-automotive-stock"> What&#8217;s Going On With Rivian Automotive Stock?</a>
Photo: Courtesy Hologic

Hologic Raises FY24 Adj EPS Forecast From $3.90-$4.10 To $3.97-$4.12 (Est $4.00), Revenue From $3.92B-$4.02B To $3.99B-$4.065B (Est $3.99B)

Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) reported its Q1 earnings results on Thursday, February 1, 2024 at 04:02 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Hologic beat estimated earnings by 3.16%, reporting an EPS of $0.98 versus an estimate of $0.95.
Revenue was down $61.00 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.05 which was followed by a 7.34% increase in the share price the next day.
Here's a look at Hologic's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.84</td>
<td>0.88</td>
<td>0.88</td>
<td>0.91</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.89</td>
<td>0.93</td>
<td>1.06</td>
<td>1.07</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>940.04M</td>
<td>957.13M</td>
<td>958.79M</td>
<td>1.00B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>945.30M</td>
<td>984.40M</td>
<td>1.03B</td>
<td>1.07B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Hologic <a href="https://www.benzinga.com/quote/HOLX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Hologic Q1 Earnings

Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) reported quarterly Adj earnings of $0.98 per share which beat the analyst consensus estimate of $0.95 by 3.16 percent. This is a 8.41 percent decrease over earnings of $1.07 per share from the same period last year. The company reported quarterly sales of $1.01 billion which beat the analyst consensus estimate of $986.12 million by 2.73 percent. This is a 5.68 percent decrease over sales of $1.07 billion the same period last year.

Hologic Q1 Adj EPS $0.98 Beats $0.95 Estimate, Sales $1.01B Beat $986.12M Estimate

AAPL

ALGM

ATKR

BALL

BrightSphere Investment Group plc Ordinary Shares

BSIG

CLFD

COLM

COUR

CSWI

CVCO

ENSG

EVBN

EXPO

FCFS

FLWS

GOOS

HUBG

Janus Henderson Group plc Ordinary Shares

KMPR

LESL

LPLA

MATW

MIXT

MTSI

OCSL

ONEW

OTEX

PFSI

POST

PTON

RACE

RVTY

SHEL

SILC

SIRI

SKYW

SRDX

TEAM

TECH

TSCO

VIAV

Earnings Scheduled For February 1, 2024

In a report released on April 7, Conor McNamara from RBC Capital maintained a Hold rating on Hologic (HOLX – Research Report), with a price target ...

RBC Capital Sticks to Its Hold Rating for Hologic (HOLX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tilray (TLRY – Research Report), Hologic (HOLX – Research Report)...

Analysts Conflicted on These Healthcare Names: Tilray (TLRY), Hologic (HOLX) and Bicycle Therapeutics (BCYC)

Needham analyst Michael Matson maintained a Buy rating on Hologic (HOLX – Research Report) today and set a price target of $90.00. Michael Matson h...

Hologic: A Strong Buy Amidst Growth, Innovation, and Favorable Market Dynamics

ClearBridge Sustainability Leaders Strategy Q1 2024 Portfolio Manager Commentary

ClearBridge Appreciation ESG Strategy Q1 2024 Portfolio Manager Commentary

Goldman's buybacks basket: Buyback growth will be 13% in 2024

Hologic to acquire breast surgical guidance firm Endomagnetics

RBC Capital analyst Conor McNamara maintained a Hold rating on Hologic (HOLX – Research Report) on April 29 and set a price target of $81.00. The c...

Hologic (HOLX) Receives a Hold from RBC Capital

Hologic Q2 2024 Earnings Preview

In a report released on April 29, Puneet Souda from Leerink Partners maintained a Buy rating on Hologic (HOLX – Research Report), with a price targ...

Hologic's Strategic Growth and Expansion: A 'Buy' Rating Analysis

ADBE

AKAM

ASML

AVGO

BCYC

BEPC

BKNG

BLDR

CBRE

CMCSA

COST

CTSH

DELL

ENPH

ETSY

EXPD

EXPE

FFIV

FOXA

FTNT

GILD

GOOG

GOOGL

INTC

JNPR

KEYS

KLAC

LRCX

MRVL

MSFT

NSRGF

NSRGY

NTAP

NVDA

QRVO

SEDG

SEMHF

SHLS

SMCI

SMMNY

SNPS

STLD

TLRY

TMUS

TSLA

VRSK

VRSN

XLRE

Press Releases

Women's Health Remains in Crisis Worldwide Even as COVID-19 Pandemic Wanes

Hologic Announces Financial Results for First Quarter of Fiscal 2024

Hologic Announces First and Only FDA-Cleared Digital Cytology System – Genius™ Digital Diagnostics System

Hologic to Webcast Presentations at Upcoming Investor Conferences

Hologic to Unveil Groundbreaking AI Research at ECR 2024

Newly Published Results Reveal a Significant Proportion of Early-Stage HR+ Breast Cancer Survivors May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing

Hologic to Announce Financial Results for the Second Quarter of Fiscal 2024 on Thursday, May 2, 2024

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Hologic Stock (NASDAQ:HOLX), Short Interest Report

People Also Watch